Data sources

Source-labeled psilocybin and psilocin literature for search, monitoring, export, and citation workflows.

How the research index is built

Eight research sources feed Psilocybin-Research.com PubMed, OpenAlex, Crossref, Europe PMC, ClinicalTrials.gov, PsyArXiv, bioRxiv, and medRxiv provide records that are reconciled into the central research index. psilocybin-research.com PubMed OpenAlex Crossref Europe PMC ClinicalTrials.gov PsyArXiv bioRxiv medRxiv
Source records are fetched, reconciled, and labeled before appearing in the live index. The original sources remain authoritative.

Research workflow

Search, filter, export, analyze, and monitor publications with source labels, publication status, citation links, alerts, API access, and a rights-safe SQLite download. Read about the methods and limitations. Explore the dataset and reuse guide or research trends by year.

Paper citation network

Design, Synthesis, and Pharmacokinetic Profiling of Fluorinated Reversible N -Alkyl Carbamate Derivatives of Psilocin for Sub-Hallucinogenic Brain Exposure

Banzato Marco, Colognesi Martina, Lucatello Lorena, Comai Stefano, Pasut Gianfranco, Capolongo Francesca, Orian Laura, Biasutto Lucia, Signor Anna, Gabbia Daniela, Manfredi Paolo L., De Martin Sara, Mattarei Andrea

Publication record · Explore literature

Public tracker catalogue and stored structured reference metadata. External references may have identifiers only. No live external citation lookup is performed.

References — this paper cites (80)

  1. Emerging mechanisms of psilocybin-induced neuroplasticity. 2025-11-01 · Expand citations
  2. Development of a PBPK model of psilocybin/psilocin from Psilocybe cubensis (magic mushroom) in mice, rats, and humans 2025-04-21 · Expand citations
  3. Synthesis and In Vitro Profiling of Psilocin Derivatives: Improved Stability and Synthetic Properties 2025-04-10 · Expand citations
  4. Pharmacokinetics of Psilocybin: A Systematic Review. 2025-03-25 · Expand citations
  5. Less is more? A review of psilocybin microdosing. 2024-10-01 · Expand citations
  6. In vitro and in vivo metabolism of psilocybin’s active metabolite psilocin 2024-04-29 · Expand citations
  7. In vivo validation of psilacetin as a prodrug yielding modestly lower peripheral psilocin exposure than psilocybin 2024-01-08 · Expand citations
  8. The Promise of Therapeutic Psilocybin: An Evaluation of the 134 Clinical Trials, 54 Potential Indications, and 0 Marketing Approvals on ClinicalTrials.gov. 2024-01-01 · Expand citations
  9. Repeated low doses of psilocybin increase resilience to stress, lower compulsive actions, and strengthen cortical connections to the paraventricular thalamic nucleus in rats. 2023-09-01 · Expand citations
  10. Psilocybin in neuropsychiatry: a review of its pharmacology, safety, and efficacy. 2023-08-01 · Expand citations
  11. Psychedelics promote plasticity by directly binding to BDNF receptor TrkB. 2023-06-01 · Expand citations
  12. Microdosing psilocybin for chronic pain: a case series. 2023-04-01 · Expand citations
  13. The Psychedelic Renaissance in Clinical Research: A Bibliometric Analysis of Three Decades of Human Studies with Psychedelics. 2023-01-01 · Expand citations
  14. Towards an understanding of psychedelic-induced neuroplasticity. 2023-01-01 · Expand citations
  15. Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study. 2022-08-02 · Expand citations
  16. The emerging science of microdosing: A systematic review of research on low dose psychedelics (1955-2021) and recommendations for the field. 2022-08-01 · Expand citations
  17. Trial of Psilocybin versus Escitalopram for Depression. 2021-04-15 · Expand citations
  18. Transcriptional regulation in the rat prefrontal cortex and hippocampus after a single administration of psilocybin. 2021-04-01 · Expand citations
  19. Emotions and brain function are altered up to one month after a single high dose of psilocybin. 2020-02-10 · Expand citations
  20. An Improved, Practical, and Scalable Five-Step Synthesis of Psilocybin 2020-01-08 · Expand citations
  21. Microdosing psychedelics: More questions than answers? An overview and suggestions for future research. 2019-09-01 · Expand citations
  22. Motives and Side-Effects of Microdosing With Psychedelics Among Users. 2019-07-01 · Expand citations
  23. Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels 2019-06-01 · Expand citations
  24. Microdosing psychedelics: personality, mental health, and creativity differences in microdosers. 2019-02-01 · Expand citations
  25. Might Microdosing Psychedelics Be Safe and Beneficial? An Initial Exploration. 2019-01-01 · Expand citations
  26. Psychiatry & the psychedelic drugs. Past, present & future. 2018-11-01 · Expand citations
  27. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. 2018-02-01 · Expand citations
  28. Psilocybin with psychological support improves emotional face recognition in treatment-resistant depression. 2018-02-01 · Expand citations
  29. Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults. 2017-12-01 · Expand citations
  30. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. 2016-12-01 · Expand citations
  31. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. 2016-12-01 · Expand citations
  32. Psychedelics. 2016-04-01 · Expand citations
  33. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. 2011-01-01 · Expand citations
  34. Concise Large-Scale Synthesis of Psilocin and Psilocybin, Principal Hallucinogenic Constituents of “Magic Mushroom” 2003-06-01 · Expand citations
  35. Renal excretion profiles of psilocin following oral administration of psilocybin: a controlled study in man 2002-09-01 · Expand citations
  36. Improvements to the Synthesis of Psilocybin and a Facile Method for Preparing the O-Acetyl Prodrug of Psilocin 1999-06-01 · Expand citations
  37. Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man 1997-06-01 · Expand citations
  38. Comparison of solution conformational preferences for the hallucinogens bufotenin and psilocin using 360-MHz proton NMR spectroscopy 1981-02-01 · Expand citations
  39. 10.1002/adhm.202301650
  40. 10.1002/jcc.1056
  41. 10.1002/jcc.21759
  42. 10.1002/wcms.1218
  43. 10.1007/s00213-013-3006-z
  44. 10.1007/s00213-018-5049-7
  45. 10.1007/s00213-018-5119-x
  46. 10.1007/s002140050353
  47. 10.1007/s10862-006-9035-8
  48. 10.1016/j.biopsych.2019.05.019
  49. 10.1016/j.bpsc.2019.12.007
  50. 10.1016/j.brainresbull.2016.04.016
  51. 10.1016/j.celrep.2018.05.022
  52. 10.1016/j.ejpb.2017.02.017
  53. 10.1016/j.jconrel.2021.11.006
  54. 10.1016/j.neubiorev.2017.03.007
  55. 10.1016/j.phrs.2025.108080
  56. 10.1016/j.vascn.2025.107622
  57. 10.1021/acs.jmedchem.3c01225
  58. 10.1021/acs.molpharmaceut.5b00464
  59. 10.1021/cr60237a002
  60. 10.1021/jm990968+
  61. 10.1038/s41386-023-01772-4
  62. 10.1038/s41392-023-01481-w
  63. 10.1038/s41598-019-49913-4
  64. 10.1038/sj.npp.1301564
  65. 10.1038/srep15216
  66. 10.1039/c8cp05922e
  67. 10.1063/1.2065267
  68. 10.1063/1.2139668
  69. 10.1103/physreva.38.3098
  70. 10.1103/physrevb.37.785
  71. 10.1126/science.adf0435
  72. 10.1155/2017/6871089
  73. 10.1155/2020/4245821
  74. 10.1177/1455072517753339
  75. 10.1177/20451253231198466
  76. 10.1186/s12954-021-00489-1
  77. 10.1371/journal.pone.0211023
  78. 10.31887/dcns.2009.11.3/cpobrien
  79. 10.3390/ijms24097754
  80. 10.3892/etm.2021.10565

Cited by — these papers cite this paper (0)

No citing papers identified in the available metadata. This does not establish that none exist.